Wednesday, July 8, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

Dupilumab 300Mg Solution for Injection

Phase 2 · small molecule · Pruritus

Dupilumab 300Mg Solution for Injection for Pruritus is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Phase 2 small molecule completed

Internal code 19-002757

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 2
Modality
small_molecule
Indication
Pruritus
Status
completed
Trials
1